Marvel Biosciences Corp.
MRVL.V
TSX
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -1.20M | -1.03M | -1.21M | -1.56M | -1.87M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 225.30K | 217.30K | 208.70K | 19.80K | 32.40K |
| Change in Net Operating Assets | 253.80K | -66.10K | 136.20K | 591.80K | 928.20K |
| Cash from Operations | -724.80K | -883.50K | -867.80K | -953.10K | -906.40K |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 0.00 | 500.00K | 500.00K | 500.00K | 1.50M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 502.60K | 500.00K | 500.00K | 0.00 | 0.00 |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -31.40K | -31.40K | -31.40K | 0.00 | 0.00 |
| Cash from Financing | 344.00K | 712.50K | 712.50K | 370.30K | 1.11M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -380.70K | -170.90K | -155.20K | -582.70K | 202.30K |